(AGI) Scoppito, June 8 - For the first time in Italy a drug isbeing given trials in a programme to calculate and cutgreenhouse gases produced during its manufacture. TheEnvironmental Effect project will determine the effects ofMaalox, which help relieves the symptoms and discomfort causedby excessive stomach acid, and will be carried out at theSanofi facility in Scoppito, the company said. "With sixfacilities throughout Italy, contributing more than 350 millioneuros to the Italian economy, 90 percent of which derives fromexports, our company boasts an extraordinary industrialpresence on the Italian pharmaceutical industrial scene," saidPresident and CEO of Sanofi Italia Alexander Zehnder. "Thisbrings with it huge responsibilities. Our sites have to conformto stringent international specifications each year and we aremaking cuts to water and electricity consumption. In some caseswe have built co-generation and tri-generation plants forinternal energy production and reduction in overallconsumption." Director of the Sanofi plant in ScoppitoAnnaletizia Baccante said "The Environmental Effect analysismarks a new chapter in the history of our facility. We areaiming to improve our awareness of environmental protection andchose Maalox as our pilot project, as it is in mass production.We are grateful to the Ministry of the Environment for allowingus to implement the project, which has enabled us to the thefirst pharmaceutical facility to define a new qualitativestandard." The Environmental Effect study, developed inconformity with the ISO/TS 14067 legislation on Maalox 400 +400 mg produced for the Italian market, has identified the mainsources of greenhouse gas emission at all stages of production:supply of raw materials, manufacture, distribution, use anddisposal, highlighting potential improvements for cuttingenergy and raw material consumption. (AGI). .